Listeria monocytogenes Cholecystitis: A Possible New Syndrome. by Bruminhent, Jackrapong et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Internal Medicine Faculty Papers &
Presentations Department of Internal Medicine
5-1-2013
Listeria monocytogenes Cholecystitis: A Possible
New Syndrome.
Jackrapong Bruminhent
Thomas Jefferson University, Jackrapong.Bruminhent@jefferson.edu
Timothy K Lynch
Thomas Jefferson University
Jonathan Gefen
Lankenau Medical Center, Wynnewood, PA
Jerome Santoro
Thomas Jefferson University, Michael.Santoro@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/internalfp
Part of the Infectious Disease Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Internal Medicine Faculty Papers & Presentations by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Bruminhent, Jackrapong; Lynch, Timothy K; Gefen, Jonathan; and Santoro, Jerome, "Listeria
monocytogenes Cholecystitis: A Possible New Syndrome." (2013). Department of Internal Medicine
Faculty Papers & Presentations. Paper 9.
http://jdc.jefferson.edu/internalfp/9
Case Report. 
 
As submitted to: 
 
The American Journal of the Medical Sciences 
 
And later published as: 
 
Listeria monocytogenes Cholecystitis: A Possible 
New Syndrome 
 
Jackrapong Bruminhent, MD, Timothy K. Lynch, MD, Jonathan 
Gefen, MD and Jerome Santoro, MD 
 
Volume 345, Issue 5, May 2013, Pages 414-417 
 
DOI: 10.1097/MAJ.0b013e3182761cda 
 
Abstract: The U.S. Food and Drug Administration 
recently added potentially fatal Listeria monocytogenes 
infection to the list of opportunistic infections that can 
occur in patients who receive tumor necrosis factor 
inhibitor therapy. In this study, the first reported case of L 
monocytogenes cholecystitis associated with etanercept 
use is described. It also appears that tumor necrosis factor 
inhibitor therapy likely increases the risk for Listeria 
cholecystitis. Clinicians need to be aware of this 
association when selecting antimicrobial therapy for these 
patients. 
 Key Indexing Terms: Cholecystitis; Tumor necrosis 
factor inhibitor; 
 
Listeria monocytogenes is an important bacterial 
pathogen among patients at the extremes of age, women 
during pregnancy and individuals who are receiving 
immunosuppressive therapy and/or have impaired cell-
mediated immunity. Central nervous system (CNS) 
infection and bacteremia are life-threatening 
manifestations of infection with this organism especially 
in immunosuppressed persons. A self-limited febrile 
gastroenteritis in immunocompetent hosts is also seen, but 
biliary tract infections such as cholecystitis are rare. To 
date, only 5 cases of L monocytogenes cholecystitis have 
been reported in the medical literature.1–3 Two of the 
cases and our case occurred in patients with rheumatoid 
arthritis being treated with tumor necrosis factor inhibitor 
therapy (TNFIT). We postulate that TNFIT is likely a 
distinct risk factor for this entity and physicians who treat 
patients with biliary tract disease need to be aware of this 
association so that they may suspect the diagnosis 
and select an appropriate antimicrobial agent in addition 
to surgical therapy. 
 
Case Report 
 
A 56-year-old African American male presented to the 
emergency department with right upper quadrant pain and 
jaundice. He had a medical history of alcoholic cirrhosis 
with minimal ascites and rheumatoid arthritis. He was 
receiving etanercept at a dosage of 25 mg/kg twice 
weekly for the preceding 5 years without infectious 
complications. He was an active alcohol user and smoker 
for years. He also reported frequent consumption of 
cheeses and other dairy products. On examination, he was 
icteric but afebrile. His heart rate was 105 beats per 
minute and blood pressure 136/70 mm Hg. An 
examination of the abdomen revealed evidence of ascites 
and tenderness in the right upper quadrant. Murphy’s sign 
was absent. 
 
Laboratory studies revealed a hemoglobin level of 11.5 
g/dL, a white blood cell count of 16 3 109 cells per liter 
with 85% neutrophils and a platelet count of 102 cells per 
nanoliter. The aspartate aminotransferase level was 73 
U/L, alanine aminotransferase level 38 U/L, alkaline 
phosphatase level 127 U/L and total bilirubin level 9.2 
mg/dL. An abdominal ultrasound revealed a distended 
and thickened gallbladder with an 8-mm gallstone. 
Hepatobiliary iminodiacetic acid scan findings were 
compatible with acute cholecystitis. The patient 
underwent laparoscopic cholecystectomy without 
complication. The pathology of the gallbladder confirmed 
the diagnosis of cholecystitis. Perioperatively, he received 
intravenous ampicillin/ sulbactam (3 g, every 6 hours) for 
3 days and was discharged home on no antimicrobial 
therapy. 
 
Two days after discharge, he was readmitted to the 
hospital because ascitic fluid was draining through his 
cholecystectomy ports and the microbiology laboratory 
reported that a bile culture obtained intraoperatively was 
growing L monocytogenes. Blood cultures that were 
negative during the first admission were repeated and 
were negative once again. Signs and symptoms of CNS 
infection were absent and a decision was made to refrain 
from performing a lumbar puncture. The patient was 
given ampicillin, 2 g every 6 hours intravenously for 5 
days and then declined additional intravenous therapy. He 
was then discharged on on oral therapy for 4 more weeks. 
During the antibiotic treatment period, his TNFIT was 
withheld. The patient was seen in follow-up 1 month after 
stopping the antibiotic and had returned to his baseline 
status. 
 
Discussion 
 
Listeria monocytogenes, a facultative anaerobic 
grampositive rod, has been receiving more attention lately 
because of its role in recent outbreaks of food-born 
illnesses. Listeria monocytogenes infection initiates with 
a gastroenteritis that often goes undiagnosed. The 
organism may be controlled at the latter stage or may go 
on to disseminate. In patients with impaired cellular 
immunity, and especially those patients receiving TNFIT, 
Listeria infections have been reported with increasing 
frequency and have been shown in many individuals 
to cause significant morbidity and mortality.4 Allerberger 
et al2 found that 2 of 467 L monocytogenes isolates were 
obtained from the gallbladder. Table 1 lists the clinical 
characteristics of our case and another 5 cases of L 
monocytogenes cholecystitis reported in the literature. 
Three patients had rheumatoid arthritis as an underlying 
condition requiring TNFIT and 2 of those received 
infliximab. All patients underwent a cholecystectomy 
combined with antibiotic treatment. Four of the 6 patients 
received ampicillin or penicillin. Bile cultures 
grew the organism in 5 of the 6 patients. Pathology 
reports revealed inflammation of the gallbladder 
compatible with cholecystitis in 4 patients and were not 
reported in 2 others. Four of these 6 patients had 
prolonged and complicated hospital courses; 1 patient 
died. 
 
Since its introduction in 1998, infliximab, the first 
tumor necrosis factor (TNF) inhibitor, has been used to 
treat a number of autoimmune diseases. Tolerability and 
therapeutic efficacy of both infliximab and etanercept are 
good, and the number of patients receiving these agents is 
increasing steadily.5  It is well known that TNFIT 
increases ones susceptibility 
to a wide variety of opportunistic pathogens including 
mycobacteria, fungi and several viruses and bacteria. The 
latter pathogens require an intact T-helper cell response 
for recovery.6 Among the reported bacterial pathogens, 
Listeria species have been recognized with increasing 
frequency. The U.S. Food and Drug Administration 
reported 26 cases of serious L monocytogenes infections 
in the literature, including 7 deaths, among patients 
treated with a TNF inhibitor.4 A systematic review and 
meta-analysis also confirmed that TNFIT increased the 
risk for serious infection.7 Our case and 2 previous case 
reports confirmed the risk for Listeria infection associated 
with TNFIT in patients with rheumatoid arthritis and, in 
particular, the risk of this pathogen as a causative 
organism in biliary tract disease. 
 
Begley et al8 postulated that Listeria may be responsible 
for enhanced biofilm formation in bile, which may 
contribute to the survival of this pathogen in the biliary 
tree. Bile tends to be resistant to bacterial growth. 
Eimerman9 characterized the growth of Listeria in bile 
and the murine gallbladder. Listeria apparently possesses 
resistance genes that allow it to overcome bile’s inherent 
bacterial toxicity. Given its tropism for the gallbladder, it 
is perhaps surprising that Listeria biliary infections are not 
observed more frequently. Nevertheless, the precise 
pathogenesis of Listeria cholecystitis is unknown. 
 
Although, the Gram’s stain of the gallbladder wall in 
our patient did not reveal gram-positive bacilli, the 
histological examination revealed inflammation of the 
gallbladder compatible with cholecystitis. In addition, the 
bile Gram’s stain showed gram-positive bacilli and the 
cultures grew L monocytogenes suggesting its 
pathological role. Previously, there have been case reports 
of Listeria infection that include septic arthritis, 
meningitis and sepsis associated with etanercept; 
this is the first confirmed case of cholecystitis.10,11 
Bacteremia and evidence of CNS infection were not 
observed in our patient. It is possible that the prompt 
institution of ampicillin/sulbactam may have prevented 
these serious sequelae. 
 
It is not proven that antibiotics are required for 
uncomplicated cholecystitis. Nevertheless, most patients 
who are hospitalized with this diagnosis do receive 
antibiotic therapy. Guidelines for the empiric selection of 
antimicrobial agents for biliary tract infections in a variety 
of clinical settings have recently been published. Agents 
such as cefazolin, ceftriaxone, cefepime, ciprofloxacin, 
levofloxacin and vancomycin either alone or in 
combination with metronidazole have been 
recommended.12 Troxler et al13 tested 71 strains of 
Listeria species and found that the organism was resistant 
to the agents listed previously with the exception of 
cefazolin and vancomycin. Importantly, Listeria CNS 
infection has been reported to develop during therapy 
with such agents as first-generation cephalosporins and 
vancomycin that have in vitro activity but do not cross the 
blood-brain barrier.14,15 
 
Ampicillin and penicillin with or without 
aminoglycosides are generally considered the preferred 
agent for Listeria infection. The addition of an 
aminoglycoside is recommended in serious infection 
because the penicillins alone are not bactericidal against 
this organism. An aminoglycoside was not administered 
to our patient due to the lack of evidence for systemic 
infection. Trimethoprim-sulfamethoxazole, a bactericidal 
agent, is thought to be the best alternative for those 
intolerant to penicillins.16 
 
The U.S. Food and Drug Administration recently added 
potentially fatal Listeria infection to the list of 
opportunistic infections that occur in patients who receive 
TNFIT.4 We believe that in suspected biliary tract 
infection in a patient who is being treated with TNFIT, 
strong consideration should be given to an antimicrobial 
agent that is able to cross the blood-brain barrier and has 
activity against Listeria. 
 
In summary, a patient who manifests signs and/or 
symptoms suggestive of infection during TNFIT must 
receive a rapid and careful evaluation, with a high 
suspicion for unusual pathogens and in particular L 
monocytogenes. In addition, TNFIT likely increases the 
risk for Listeria cholecystitis. Physicians should consider 
L monocytogenes as a cause of cholecystitis in patients 
who are receiving TNFIT to initiate appropriate treatment 
and hopefully reduce the potentially severe morbidity and 
mortality associated with this pathogen. 
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